ROIV
Roivant Sciences Ltd. NASDAQ$28.36
Mkt Cap $20.3B
52w Low $10.58
90.0% of range
52w High $30.33
50d MA $28.29
200d MA $20.62
P/E (TTM)
-116.0x
EV/EBITDA
-4.3x
P/B
3.9x
Debt/Equity
0.0x
ROE
-14.2%
P/FCF
-8.7x
RSI (14)
—
ATR (14)
—
Beta
1.21
50d MA
$28.29
200d MA
$20.62
Avg Volume
6.0M
About
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 6, 2026 | AMC | -0.30 | -0.24 | +19.9% | 25.82 | +2.1% | +7.2% | +5.9% | +3.8% | +3.6% | +2.4% | — |
| Nov 10, 2025 | AMC | -0.32 | -0.28 | +12.4% | 21.17 | +0.5% | -1.3% | +0.7% | -2.9% | -4.2% | -2.9% | — |
| Aug 11, 2025 | AMC | -0.25 | -0.18 | +27.9% | 11.17 | +1.2% | +3.6% | +7.1% | +5.2% | +6.1% | +5.7% | — |
| May 29, 2025 | AMC | -0.26 | -0.22 | +16.5% | 11.30 | +0.0% | -2.7% | -1.2% | -0.4% | -0.8% | -0.9% | — |
| Feb 10, 2025 | AMC | -0.24 | -0.13 | +45.8% | 10.79 | -0.3% | -2.8% | -3.2% | -3.2% | -2.1% | -1.0% | — |
| Nov 12, 2024 | AMC | -0.25 | -0.29 | -17.4% | 11.64 | +1.6% | +2.7% | +0.0% | -3.8% | -4.1% | -2.8% | — |
| Aug 8, 2024 | AMC | -0.24 | -0.18 | +26.0% | 10.85 | +0.0% | +2.5% | +3.0% | +4.7% | +5.3% | +4.2% | — |
| May 30, 2024 | AMC | -0.26 | -0.23 | +13.0% | 10.39 | +1.1% | -0.3% | +4.5% | +3.3% | +4.7% | +2.2% | — |
| Feb 13, 2024 | AMC | -0.27 | -0.21 | +22.2% | 10.80 | +0.0% | +4.8% | +6.0% | +7.3% | +6.9% | +6.9% | — |
| Nov 13, 2023 | AMC | -0.28 | -0.26 | +7.1% | 9.05 | +3.9% | +2.8% | +0.2% | -0.3% | -0.9% | -2.8% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 16 | Piper Sandler | Maintains | Overweight → Overweight | — | $29.39 | $29.65 | +0.9% | -0.7% | +1.5% | -1.1% | -0.3% | -0.8% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.85 | $28.44 | +2.1% | +6.0% | +6.7% | +3.3% | +6.0% | +6.6% |
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.67 | $27.50 | -0.6% | -1.2% | -3.1% | -3.3% | -4.4% | -2.1% |
| Feb 10 | Citigroup | Maintains | Buy → Buy | — | $27.67 | $27.50 | -0.6% | -1.2% | -3.1% | -3.3% | -4.4% | -2.1% |
| Feb 9 | Guggenheim | Maintains | Buy → Buy | — | $25.82 | $26.35 | +2.1% | +7.2% | +5.9% | +3.8% | +3.6% | +2.4% |
| Dec 15 | Leerink Partners | Maintains | Outperform → Outperform | — | $22.10 | $22.20 | +0.5% | -0.9% | +3.8% | +2.7% | -1.4% | +1.4% |
| Dec 15 | Goldman Sachs | Maintains | Buy → Buy | — | $22.10 | $22.20 | +0.5% | -0.9% | +3.8% | +2.7% | -1.4% | +1.4% |
| Dec 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.34 | $21.77 | +2.0% | +3.6% | +2.6% | +7.5% | +6.4% | +2.1% |
| Nov 11 | Citigroup | Maintains | Buy → Buy | — | $21.17 | $21.27 | +0.5% | -1.3% | +0.7% | -2.9% | -4.2% | -2.9% |
| Oct 29 | Citigroup | Maintains | Buy → Buy | — | $18.41 | $18.36 | -0.3% | +1.9% | +6.4% | +8.6% | +6.5% | +7.9% |
Recent Filings
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Immunovant's batoclimab Phase 3 thyroid eye disease data and brepocitinib advancement could drive near-term clinical catalysts, but investors should await detailed results to assess commercial viability and likelihood of regulatory approval.
Apr 2
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
Settlement with Moderna likely ends costly litigation risk for these biotech companies, potentially freeing resources for R&D and improving profit visibility going forward.
Mar 23
8-K · 8.01
!! High
Roivant Sciences Ltd. Common Shares -- 8-K 8.01: Material Event / Announcement
Roivant Sciences doubled its share repurchase authorization to $1 billion, signaling management confidence in the stock's valuation and commitment to returning capital to shareholders.
Mar 3
8-K · 7.01
! Medium
Roivant Sciences Ltd. Common Shares -- 8-K 7.01: Regulation FD Disclosure
Roivant Sciences' FDA acceptance of brepocitinib's NDA with Priority Review for dermatomyositis treatment accelerates the potential approval timeline for this subsidiary asset.
Mar 3
8-K
Roivant Sciences Ltd. Common Shares -- 8-K Filing
Roivant Sciences' brepocitinib showed positive Phase 2 results for cutaneous sarcoidosis, significantly outperforming placebo with a 21.6-point efficacy advantage, supporting potential regulatory approval and commercial viability.
Feb 6
Data updated apr 26, 2026 11:20pm
· Source: massive.com